慢性閉塞性肺疾患の急性悪化に対するカルボシステインの効果 (PEACE研究):ランダム化プラセボ対照試験
Jin-Ping Zheng1, Jian Kang, Shao-Guang Huang
1Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China.
Lancet (London, England)
|June 17, 2008
まとめ
カーボシステインは,慢性阻害性肺疾患 (COPD) の中国人患者における年間悪化を著しく減少させた. この粘液駆除剤は,COPDの悪化に対する価値ある予防治療の選択肢を提供します.
科学分野:
- 呼吸器医学とは
- 薬理学 薬理学とは
- クリニック・トライアル 臨床試験
背景:
- 慢性阻害性肺疾患 (COPD) は,空気流の制限,粘液の過剰分泌,酸化ストレス,炎症を含む.
- カーボシステインは,抗炎症および抗酸化特性を実証した粘液分解剤です.
研究 の 目的:
- COPDと診断された患者の年間悪化率を低減するカルボシステインの有効性を評価する.
- COPDの悪化に対する予防療法としてのカルボシステインの可能性を評価する.
主な方法:
- ランダム化,ダブルブラインド,プラセボ対照試験は,中国で,適格なCOPD患者709人を対象に1年間にわたって実施されました.
- 患者は毎日1500mgのカルボシステインまたはプラセボを投与された.
- 主要エンドポイントは,1年間の研究期間中のCOPD悪化率であり,治療の意図によって分析されました.
主要な成果:
- カーボシステインは,プラセボと比較して年間平均悪化率を有意に低下させました (年1人の患者当たり1.01対1.35の悪化率,p=0.004).
- カーボシステイン群の悪化のリスク比率は0.75 (95%CI 0.62-0.92) でした.
- COPDの重症度,喫煙状態,または同時に吸入されたコルチコステロイドの使用に関する有意な相互作用は観察されなかった.
結論:
- カーボシステインは,中国人のCOPD患者の悪化を防ぐために,耐受性があり効果的な治療法です.
- カーボシステインのような粘液駆除剤は,COPDの悪化を予防するための貴重な治療選択肢と見なされるべきである.
関連する概念動画
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.